Saisei Ventures has appointed Dr. Sven Kili, former CEO of Antion Biosciences and leader at GlaxoSmithKline and Sanofi-Genzyme, as a partner. Based in Cambridge, Massachusetts, and Tokyo, Saisei Ventures focuses on Japanese biotechnology and therapeutic innovations. Kili expressed enthusiasm for using his experience in cell and gene therapies to support entrepreneurs developing impactful therapies. Saisei Ventures, launched in 2021 by Healios, has secured investments from major funds, including a $30 million commitment from the Japan Investment Corporation. Managing partner Jonathan Yeh highlighted Kili’s expertise as a valuable addition to their mission in the global biotech landscape.